Topics

Pharmacokinetics of Teicoplanin in Intensive Care and Haematology Patients

2019-09-25 06:13:36 | BioPortfolio

Summary

Characterize teicoplanin PK in critically ill patients with a specific focus on alterations of exposure due to variability in renal function.

In a prospective, observational, open-label study the investigators aim to define PK of free drug concentrations of teicoplanine in ICU and heamatology patients and define a PK model for Bayesian dose individualization.

Description

Bacterial infection with coagulase-negative staphylococci (CNS) or methicillin resistant and sensitive staphylococcus aureus(MRSA/MSSA) indicates poor prognosis and increased mortality in critically ill patients.

With the current emergence of glycopeptide-intermediate sensitive Staphylococcus aureus strains, personalized dosing of teicoplanin is of utmost importance to preserve the current therapeutic armamentarium.

Teicoplanin is considered equipotent to vancomycin, albeit safer with minimal nephrotoxicity. It is estimated that 50% of all critically ill patients treated with teicoplanin does not reach target exposure. This is the major driver for treatment failure and development of resistance and dose individualization will overcome this problem.

Our project is aimed at developing and implementing a personalized dosing strategy for teicoplanin, to prevent development of glycopeptide resistance and allow safe treatment of glycopeptide intermediate sensitive bacteria.

In a prospective clinical study, critically ill patients (defined as ICU and hematology patients) who receive teicoplanin as standard care for antimicrobial treatment will be eligible for inclusion. Minimally invasive blood sampling for pharmacokinetic analysis will be retrieved through an indwelling central venous catheter or an arterial line (9 samples per patient). Teicoplanin total and free drug concentrations will be measured using a validated analytical assay. A total of 30 patients will be included.

We will develop a population PK model using nonlinear mixed effects modelling for total and unbound teicoplanin to characterize the magnitude of inter-individual variability in PK parameters (clearance, distribution volume), and to identify patient-derived characteristics that can predict such variability in a critically ill patient population.

Study Design

Conditions

Bacterial Infections

Intervention

No intervention

Location

Radboud University Medical Center
Nijmegen
Gelderland
Netherlands

Status

Not yet recruiting

Source

Radboud University

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-09-25T06:13:36-0400

Clinical Trials [1113 Associated Clinical Trials listed on BioPortfolio]

Bacterial Infections in Patients With Cirrhosis in Argentina: Clinical and Microbiological Characteristics

In recent years, there has been an increasing prevalence of bacterial infections caused by multiresistant and extremely resistant organisms in patients with cirrhosis. These infections are...

Procalcitonin Level and Kinetics in Children With Bacterial Infections

The purposes of this study are: 1. To determine whether procalcitonin level at admission of pediatric patients with bacterial infections can be used as a marker for prediction of d...

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

This study compares 2 different treatments administered to try to prevent serious bacterial infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin pl...

OR PathTrac (Tracking Intra-operative Bacterial Transmission)

Healthcare-associated infections occur frequently and are associated with patient harm. These infections are becoming more difficult to treat due to antibiotic resistance. It is important ...

biomArkers to differeNtiate bacTerial From vIral iNfEctions

ANTOINE is a prospective trial which aims to assess diagnostic performance of 7 biomarkers for the diagnosis of severe bacterial infections (SBI) in children aged from 7 days to 36 months....

PubMed Articles [10430 Associated PubMed Articles listed on BioPortfolio]

Widespread antimicrobial resistance among bacterial infections in a Rwandan referral hospital.

Resistance among bacterial infections is increasingly well-documented in high-income countries; however, relatively little is known about bacterial antimicrobial resistance in low-income countries, wh...

Bacterial footprints in aspirate of infarct-related artery in ST-elevation myocardial infarction patients underwent primary percutaneous coronary intervention.

Bacterial infections can trigger acute coronary syndromes. This study aimed to examine bacterial footprints in the aspirate of infarct-related artery.

Common bacterial infections and their treatment in hospitalized pediatric patients.

Common bacterial infections in pediatric patients that the hospital pharmacist may encounter are reviewed, and guidance on the safe and effective use of antibiotics to treat those infections is provid...

Epidemiology of Serious Bacterial Infections in Infants Less Than 90 Days in a Military Health System Cohort.

Management of suspected serious bacterial infections (SBIs) in infants less than 3 months old is challenging. Understanding the epidemiology of SBI is necessary to inform management decisions. Recent ...

Prosthetic fungal infections: poor prognosis with bacterial co-infection.

The aims of this study were to report the efficacy of revision surgery for patients with co-infective bacterial and fungal prosthetic joint infections (PJIs) presenting to a single institution, and to...

Medical and Biotech [MESH] Definitions

Bacterial infections of the brain, spinal cord, and meninges, including infections involving the perimeningeal spaces.

Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process.

Inflammation of the lung parenchyma that is caused by bacterial infections.

Infections by bacteria, general or unspecified.

Infections caused by bacteria and fungi, general, specified, or unspecified.

More From BioPortfolio on "Pharmacokinetics of Teicoplanin in Intensive Care and Haematology Patients"

Quick Search

Relevant Topics

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Trial